Stock Watch: Unnatural Selection In Clinical Trials
Have We Been Doing It Wrong All These Years?
Executive Summary
Patient selection is held out as the Achilles heel of clinical trial success. But a surprise and fortunate finding in Pfizer’s gene therapy trial has already resulted in tightened recruitment criteria, thanks to genetic analysis.
You may also be interested in...
Stock Watch: Digging Holes And Clutching At Straws In Biotech R&D
Biotech CEOs often express surprise when the FDA rejects their drugs. But collaborative interactions between regulators and drug sponsors count for little if the latter fail to adjust their clinical and regulatory efforts accordingly.
Stock Watch: The Swings And Roundabouts Of KRAS Inhibitor Competition
The era of follow-on medicinal chemistry has largely been eliminated by more comprehensive patent protection. Nowadays, investors trade on the differences in safety and efficacy for similar molecules.
Stock Watch: Wrap Up For The Biotech Winter
A drastic risk-off pullback in the public market can close an IPO window while private biotechs aspiring for either a public debut or an acquisition by big pharma may be stymied by their stale valuations.